# Decentralized N=1 Study: A Feasible Approach to Evaluate Individual Therapy Response to Dapagliflozin.

> **NCT06374043** · PHASE4 · COMPLETED · sponsor: **University Medical Center Groningen** · enrollment: 20 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2
- Diabetes Mellitus Type 2 With Proteinuria
- Diabetes Mellitus
- Diabetes
- Diabetes Complications
- Albuminuria
- Chronic Kidney Diseases
- Chronic Kidney Disease Due to Type 2 Diabetes Mellitus
- CKD
- Proteinuria

## Interventions

- **DRUG:** Dapagliflozin 10mg Tab
- **DRUG:** Placebo
- **DEVICE:** Withings BPM Connect
- **DEVICE:** Withings Body+
- **DIAGNOSTIC_TEST:** Hem-Col Capillary Blood Collection Device
- **DEVICE:** MEMS (Medication Electronic Monitoring System) Cap
- **BEHAVIORAL:** Questionnaire: participants' perspectives toward remote data collection

## Key facts

- **NCT ID:** NCT06374043
- **Lead sponsor:** University Medical Center Groningen
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-05-11
- **Primary completion:** 2022-09-13
- **Final completion:** 2022-09-13
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2024-04-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06374043

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06374043, "Decentralized N=1 Study: A Feasible Approach to Evaluate Individual Therapy Response to Dapagliflozin.". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06374043. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*